CARsgen Therapeutics Holdings Ltd.

As of December 31, 2025, CARsgen Therapeutics Holdings Ltd. carries a market capitalization of 8.11B, placing it among publicly traded companies globally. Its enterprise value stands at 6.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CARsgen Therapeutics Holdings Ltd.'s next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, CARsgen Therapeutics Holdings Ltd. has 546.16M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, CARsgen Therapeutics Holdings Ltd. maintains a current ratio of 5.73, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, CARsgen Therapeutics Holdings Ltd.'s stock has declined approximately 32.27% over the past 52 weeks. The 50-day moving average sits at 12.86, while the 200-day moving average is 15.69.

As of December 31, 2025, CARsgen Therapeutics Holdings Ltd. holds 1.24B in cash and equivalents against 68.08M in total debt, resulting in a net debt position of -1.24B. Total book value stands at 871.75M, with working capital of 1.08B providing operational flexibility.